ClinicalTrials.gg
CompletedNCT01006629Updated Jul 19, 2011Results posted

Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

A Phase 2/3 interventional study of palivizumab in Respiratory Syncytial Virus Infection, Premature Birth and Bronchopulmonary Dysplasia, sponsored by Abbott. Completed at 19 sites in Russian Federation. Open to participants aged Up to 2 Years. Per ClinicalTrials.gov, last updated 2011-07-19.

Sponsored by Abbott · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
Up to 2 Years
Sex
All
01

Study summary

100 Russian children of 2 years of age and less in high-risk populations (preterm, and/or with heart and lung problems) will receive palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe respiratory syncytial virus (RSV) infection in order to study the safety and efficacy of the drug in Russian subjects.

Read the detailed description

A prospective, multicenter, open-label, non-comparative study of safety and efficacy of palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe lower respiratory tract respiratory syncytial virus infection in 100 Russian children of 2 years of age and less in high-risk populations (preterm infants [less than or equal to 35 weeks gestational age], infants with bronchopulmonary dysplasia [BPD], and infants with hemodynamically significant congenital heart disease [HSCHD]).

02

Conditions studied

  • Respiratory Syncytial Virus Infection
  • Premature Birth
  • Bronchopulmonary Dysplasia
  • Congenital Heart Disease

Keywords

  • Efficacy of palivizumab
  • Respiratory syncytial virus (RSV) infection
  • Prevention of severe RSV infection
  • Preterm infants
  • Infants with bronchopulmonary dysplasia
  • Infants with hemodynamically significant congenital heart disease
03

In context

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

This study's enrollment of 100 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.

Browse Respiratory Syncytial Virus Infections studies →

Lead sponsor

Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following criteria to be enrolled into the study:

  1. Infants at high risk of severe RSV infection defined as fulfilling at least one of the following:

    • Infants born at less than or equal to 35 weeks gestational age AND are less than or equal to 6 months of age at enrollment
    • Infants less than or equal to 24 months of age at enrollment AND with a diagnosis of bronchopulmonary dysplasia (defined as oxygen requirement at a corrected gestational age of 36 weeks) requiring intervention/management (i.e., oxygen, diuretics, bronchodilators, , etc.) anytime within 6 months prior to enrollment
    • Infants less than or equal to 24 months of age at enrollment with hemodynamically significant congenital heart disease, either cyanotic or acyanotic, unoperated or partially corrected. Children with acyanotic cardiac lesions must have pulmonary hypertension (greater than or equal to 40 mmHg measured pressure in the pulmonary artery [ultrasound acceptable]) or the need for daily medication to manage congenital heart disease. Children with the following conditions are not eligible: hemodynamically insignificant small atrial or ventricular septal defects, patent ductus arteriosis, children with aortic stenosis, pulmonic stenosis, or coarctation of the aorta alone.
  2. Form signed by parent(s).

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria are not eligible for the study:

  1. Hospitalization at the time of enrollment (unless discharge is anticipated within 14 days).
  2. Mechanical ventilation (including continuous positive airway pressure [CPAP]) at the time of enrollment.
  3. less than 6 months.
  4. Active respiratory illness, or other acute infection.
  5. Known renal impairment, as determined by the investigator.
  6. Known hepatic impairment, as determined by the investigator.
  7. History of seizures (except neonatal seizures).
  8. Unstable neurological disorder (includes, but is not restricted to, epilepsy and decompensated hydrocephaly).
  9. Known immunodeficiency, as determined by the investigator.
  10. Allergy to immunoglobulin products.
  11. Prior receipt of RSV vaccine or prophylaxis (e.g., palivizumab or motavizumab), or administration of a product possibly containing RSV-neutralizing antibody within 100 days prior to enrollment (includes, but is not restricted to, the following: RSV hyperimmunoglobulin, polyclonal intravenous immunoglobulin, cytomegalovirus hyperimmunoglobulin, varicella zoster hyperimmunoglobulin).
  12. Participation in another clinical trial within 30 days prior to enrollment.
  13. Previous enrollment in this trial.
  14. For any reason, subject is considered by the investigator to be an unsuitable candidate for this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    palivizumab

    palivizumab 15 mg/kg intramuscularly every 30 days for 3 to 5 injections

    Biological: palivizumab

Interventions

  • Biologicalpalivizumab

    palivizumab 15 mg/kg intramuscularly

    Also known as: ABT-315 (MEDI-493), Synagis 15 mg/kg intramuscularly

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events

    Treatment-emergent adverse events were defined as those occurring after study drug initiation and within 30 and 100 days after the last dose of study drug. The number of subjects experiencing a serious or nonserious treatment-emergent adverse event within 30 days after the last dose of study drug is summarized. See the Reported Adverse Events section for details.

    Time frame: Through 30 days following the last injection of palivizumab

  2. Number of Hospitalizations Due to Respiratory Syncytial Virus (RSV)

    Number of subjects experiencing an RSV hospitalization

    Time frame: Through 30 days following the last injection of palivizumab

Secondary outcomes

  1. Total Number of RSV Hospitalization Days

    All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.

    Time frame: Through 30 days following the last injection of palivizumab

  2. Total RSV Hospitalization Days With Increased Supplemental Oxygen Requirement

    All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.

    Time frame: Through 30 days following the last injection of palivizumab

  3. Number of Intensive Care Unit (ICU) Admissions During RSV Hospitalization

    Outcome measure refers to the number of subjects admitted to the ICU during RSV hospitalization. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.

    Time frame: Through 30 days following the last injection of palivizumab

  4. Total Days of RSV ICU Stay

    All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.

    Time frame: Through 30 days following the last injection of palivizumab

  5. Number of Subjects Who Received Mechanical Ventilation During RSV Hospitalization

    All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.

    Time frame: Through 30 days following the last injection of palivizumab

  6. Total Days of Mechanical Ventilation During RSV Hospitalization

    All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.

    Time frame: Through 30 days following the last injection of palivizumab

07

Results

Posted Jul 19, 2011
Limitations and caveats
This study had no control group; relative comparisons are only possible with current product information for palivizumab. No RSV hospitalizations occurred during the study; therefore, secondary outcome measures could not be evaluated.

Participant flow

Subjects were enrolled into the study in 3 geographic areas of the Russian Federation. Recruitment began in November 2009 and ended in December 2009. Subjects at high risk of severe RSV infection (including preterm infants, infants with BPD, and infants with HSCHD) were identified as candidates for the study on the basis of routine assessments.

Participant flow — Overall Study
MilestonePalivizumab
Started100
Completed94
Not completed6
Withdrew: Adverse event1
Withdrew: Parent refused to continue participation1
Withdrew: Parent unable to perform site visit4

Outcome measures

PrimaryFrequency of Adverse Events

Treatment-emergent adverse events were defined as those occurring after study drug initiation and within 30 and 100 days after the last dose of study drug. The number of subjects experiencing a serious or nonserious treatment-emergent adverse event within 30 days after the last dose of study drug is summarized. See the Reported Adverse Events section for details.

Time frame:
Through 30 days following the last injection of palivizumab
Reported as:
Number · participants
Frequency of Adverse Events
participantsPalivizumab
Frequency of Adverse Events41
PrimaryNumber of Hospitalizations Due to Respiratory Syncytial Virus (RSV)

Number of subjects experiencing an RSV hospitalization

Time frame:
Through 30 days following the last injection of palivizumab
Reported as:
Number · participants
Number of Hospitalizations Due to Respiratory Syncytial Virus (RSV)
participantsPalivizumab
Number of Hospitalizations Due to Respiratory Syncytial Virus (RSV)0 (0.0 to 3.6)
SecondaryTotal Number of RSV Hospitalization Days

All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.

Time frame:
Through 30 days following the last injection of palivizumab
Reported as:
Mean · days

No measurements were reported for this outcome.

SecondaryTotal RSV Hospitalization Days With Increased Supplemental Oxygen Requirement

All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.

Time frame:
Through 30 days following the last injection of palivizumab
Reported as:
Mean · days

No measurements were reported for this outcome.

SecondaryNumber of Intensive Care Unit (ICU) Admissions During RSV Hospitalization

Outcome measure refers to the number of subjects admitted to the ICU during RSV hospitalization. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.

Time frame:
Through 30 days following the last injection of palivizumab
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryTotal Days of RSV ICU Stay

All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.

Time frame:
Through 30 days following the last injection of palivizumab
Reported as:
Mean · days

No measurements were reported for this outcome.

SecondaryNumber of Subjects Who Received Mechanical Ventilation During RSV Hospitalization

All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.

Time frame:
Through 30 days following the last injection of palivizumab
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryTotal Days of Mechanical Ventilation During RSV Hospitalization

All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.

Time frame:
Through 30 days following the last injection of palivizumab
Reported as:
Mean · days

No measurements were reported for this outcome.

Adverse events

Collected over From date of first dose of study drug through 100 days after the last dose of study drug. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palivizumab—10/100 (10%)39/100 (39%)
Most frequent serious events
Most frequent serious events
EventPalivizumab
BronchitisInfections and infestations4/100
EnteritisGastrointestinal disorders3/100
Supraventricular tachycardiaCardiac disorders1/100
PneumoniaInfections and infestations1/100
TonsillitisInfections and infestations1/100
Upper respiratory tract infectionInfections and infestations1/100
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPalivizumab
RhinitisInfections and infestations19/100
Upper respiratory tract infectionInfections and infestations8/100
BronchitisInfections and infestations3/100
Bronchopulmonary dysplasiaRespiratory, thoracic and mediastinal disorders3/100
TeethingGastrointestinal disorders2/100
Ear infectionInfections and infestations2/100
NasopharyngitisInfections and infestations2/100
Respiratory tract infectionInfections and infestations2/100
Respiratory tract infection viralInfections and infestations2/100
NervousnessPsychiatric disorders2/100

Baseline characteristics

Age Continuous
Age Continuous(months)Palivizumab
Mean8.2 ± 6.3
Age, Customized
Age, Customized(participants)Palivizumab
Between 0 and 3 months28
Between 4 and 6 months24
Between 7 and 9 months14
Between 10 and 12 months7
Between 13 and 15 months8
Between 16 and 18 months10
Between 19 and 21 months5
Between 22 and 24 months4
Sex: Female, Male
Sex: Female, Male(Participants)Palivizumab
Female52
Male48
Region of Enrollment
Region of Enrollment(participants)Palivizumab
Russian Federation100
Gestational Age
Gestational Age(weeks)Palivizumab
Mean33.4 ± 5.1
Gestational Age, categorical
Gestational Age, categorical(participants)Palivizumab
Less than 29 weeks gestational age23
Between 29 and 32 weeks gestational age22
Between 33 and 35 weeks gestational age22
Greater than 35 weeks gestational age33
Infants born <= 35 weeks gestational age and <= 6 months of age at enrollment
Infants born <= 35 weeks gestational age and <= 6 months of age at enrollment(participants)Palivizumab
Yes33
No67
Infants <= 24 months of age at enrollment and with a diagnosis of BPD
Infants <= 24 months of age at enrollment and with a diagnosis of BPD(participants)Palivizumab
Yes46
No54

1 further baseline measures are reported on the registry.

08

Study locations

19 sites
  • Site Ref # / Investigator 22699
    Ivanovo, 153731, Russian Federation
  • Site Ref # / Investigator 22694
    Kazan, 420012, Russian Federation
  • Site Ref # / Investigator 24022
    Moscow, 117198, Russian Federation
  • Site Ref # / Investigator 15744
    Moscow, 117931, Russian Federation
  • Site Ref # / Investigator 15745
    Moscow, 117997, Russian Federation
  • Site Ref # / Investigator 24025
    Moscow, 117997, Russian Federation
  • Site Ref # / Investigator 15781
    Moscow, 119991, Russian Federation
  • Site Ref # / Investigator 22686
    Moscow, 119991, Russian Federation
  • Site Ref # / Investigator 15747
    Moscow, 125412, Russian Federation
  • Site Ref # / Investigator 22696
    Novosibirsk, 630091, Russian Federation
  • Site Ref # / Investigator 24023
    Novosibirsk, 630091, Russian Federation
  • Site Ref # / Investigator 22692
    Saint Petersburg, 193312, Russian Federation
  • Site Ref # / Investigator 22683
    Saint Petersburg, 194100, Russian Federation
  • Site Ref # / Investigator 22693
    Saint Petersburg, 194291, Russian Federation
  • Site Ref # / Investigator 22685
    Saint Petersburg, 196650, Russian Federation
  • Site Ref # / Investigator 15722
    Saint Petersburg, 197022, Russian Federation
  • Site Ref # / Investigator 15748
    Saint Petersburg, 198205, Russian Federation
  • Site Ref # / Investigator 15782
    Saint Petersburg, 198205, Russian Federation
  • Site Ref # / Investigator 15746
    Tomsk, 634012, Russian Federation
09

References and documents

Publications

  • Turti TV, Baibarina EN, Degtiareva EA, Keshishyan ES, Lobzin YV, Namazova-capital VE, Cyrillicaranova LS, Prodeus AP, Gudkov KM, Kruglova AI, Schulz GA, Notario GF. A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation. BMC Res Notes. 2012 Sep 4;5:484. doi: 10.1186/1756-0500-5-484. PubMed 22943074 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Apr 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2009
First posted
Nov 3, 2009
Start
Nov 2009
Primary completionActual
Apr 2010
CompletionActual
Jul 2010
Results first posted
Jul 19, 2011
Last update
Jul 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01006629
Lead sponsor
Abbott
First posted
Nov 3, 2009
Start date
Nov 2009
Primary completion
Apr 2010
Completion
Jul 2010
Results posted
Jul 19, 2011
Last update
Jul 19, 2011

Study contacts

Konstantin M Gudkov, MD
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palivizumab

Start the discussion